Much work on the therapeutic potential of genetic or pharmacological inhibition of ILK has been carried out, demonstrating significant downregulation of various oncogenic signaling pathways and thus suppression of tumor development and progression in several cancer types upon ILK’s “deactivation” [100, 101, 126, 237–244]. The gene discussed is ILK; the disease is neoplasm.